Arcturus Therapeutics Holdings Inc. Earnings Recaps
Q2 2026
Aug 8, 2026
Arcturus shares surged 18.4% as the market rewarded the regained global rights to its validated sa-mRNA vaccine platform and KOSTAIVE COVID vaccine, along with a $12 million upfront payment and removal of $16 million in liabilities. This strategic move clearly outshined ongoing development progress in rare disease programs that remain largely in clinical stages.
Key takeaways
- Regained full global rights to KOSTAIVE COVID vaccine and broader infectious disease sa-mRNA platform, providing strategic control and commercial flexibility.
- Received $12 million cash payment from CSL Seqirus and eliminated approximately $16 million in related liabilities, positively impacting the balance sheet.
- Ongoing Phase II clinical studies for ARCT-032 (cystic fibrosis) and ARCT-810 (OTC deficiency) advancing as planned, with Phase II enrollment completed for ARCT-810; data readouts expected later this year.
- Expansion of ARCT-032 trial enrollment into Israel and Turkey to access higher prevalence patient populations with null CF mutations, potentially accelerating recruitment.
- No updates provided on financial results or near-term commercial revenue streams beyond the vaccine portfolio transaction.
Q1 2026
May 11, 2026
Shares fell 3.0% as investors appeared unsettled by a cautious outlook and the early-stage nature of clinical progress, with no new commercial or financial guidance provided to offset ongoing development risks.
Key takeaways
- ARCT-032 CF program advanced into a 12-week Phase II open-label study, focusing on safety, tolerability, and early lung function endpoints in Class I CF patients.
- The repeated dosing beyond one month, a historic challenge for inhaled mRNA therapies, is underway but remains exploratory without efficacy data presented.
- ARCT-810 OTC deficiency program received FDA feedback outlining a pediatric pivotal trial pathway, with additional exploratory data being collected ahead of an End of Phase II meeting later this year.
- Commercial guidance for KOSTAIVE COVID vaccine in Japan remains delegated to partner Meiji, with no updated financial targets disclosed by Arcturus.
- Leadership additions in finance and medical roles signal internal strengthening but do not mitigate uncertainties around clinical or commercial milestones.